Losartan Therapy in Pulmonary Hypertension
Information source: Baskent University
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pulmonary Hypertension
Intervention: nifedipine, losartan (Drug); losartan (Drug); Nifedipine, losartan (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Baskent University Official(s) and/or principal investigator(s):
Serife Savas Bozbas, MD, Principal Investigator, Affiliation: Baskent University Faculty of Medicine, Department of Pulmonary Disease
Fusun Oner Eyuboglu, MD, Study Chair, Affiliation: Baskent University Faculty of Medicine, Department of Pulmonary Disease
Summary
In addition to being effective vasodilators, angiotensin-converting enzyme inhibitors (ACEIs)
and angiotensin receptor blockers (ARBs) exert neurohumoral inhibitory actions, such as the
inhibition of vascular remodeling and smooth muscle cell proliferation and the amelioration
of endothelial dysfunction. These beneficial effects, render those agents appropriate for use
in the treatment of pulmonary hypertension. However, data regarding the use of ACEIs or ARBs
in the treatment of PHT are limited. In this study, efficacy of an ARB, losartan was
compared with those of the calcium channel blocker, nifedipine in the treatment of pulmonary
hypertension using echocardiographic, 6-minute walk test (6MWT), cardiopulmonary exercise
test, and endothelin-1 levels. Losartan is as effective as nifedipine for reducing Doppler
echocardiographically measured PAP and improving exercise capacity on 6MWT and CPET. However
the short-term use of losartan or nifedipine had no statistically significant effect on
endothelin-1 levels in patients with PHT.
Clinical Details
Official title: Losartan Decreases Pulmonary Artery Pressure and Improves Exercise Capacity in Patients With Pulmonary Hypertension
Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Pulmonary hypertension diagnosed by Doppler echocardiographic examination (a mean
pulmonary artery pressure of > 26mmHg)
Exclusion Criteria:
- acute infectious or inflammatory disease,
- exacerbation of chronic obstructive pulmonary disease,
- malignancy,
- acute coronary syndrome in the last 4 weeks,
- uncontrolled arrhythmia and hypertension,
- decompensated heart failure,
- acute pulmonary emboli,
- thrombus in a lower extremity,
- oxygen saturation below 85% at rest,
- failure to cooperate with CPET
Locations and Contacts
Additional Information
Starting date: January 2005
Ending date: July 2005
Last updated: August 22, 2007
|
